<DOC>
	<DOCNO>NCT00004165</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase III trial study effectiveness melphalan follow peripheral stem cell transplantation treat patient multiple myeloma .</brief_summary>
	<brief_title>Melphalan Followed Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Administer standard , high dose melphalan safely closely monitored set patient responsive multiple myeloma . - Determine cost time effectiveness collection sufficient peripheral blood stem cell ( PBSC ) two high dose melphalan therapy PBSC transplantation patient population . OUTLINE : Patients remission receive 3-6 course remission induction therapy consist either anthracycline/glucocorticoid regimen high dose glucocorticoid . At 21-45 day follow induction therapy , patient receive filgrastim ( G-CSF ) subcutaneously daily 4 day follow daily peripheral blood stem cell ( PBSC ) collection begin day 4 continue target number cell reach . At 5 day 6 week follow PBSC collection , patient receive high dose melphalan IV 2 hour 2 consecutive day . At 36-48 hour follow completion melphalan , patient receive infusion PBSC follow G-CSF subcutaneously daily blood count recover . At 3 month 5 year follow high dose therapy PBSC infusion , patient evidence disease progression receive additional treatment high dose melphalan follow PBSC infusion first course . Patients follow 30-45 day , 6 month , annually thereafter . PROJECTED ACCRUAL : A total 60-120 patient accrue study 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed active multiple myeloma define : Lytic disease Anemia Hypercalcemia Secondary renal insufficiency More 400 mg/24 hour urinary protein excretion Symptomatic hyperviscosity If previously treat , refractory 1 regimen Primary amyloidosis without subsequent multiple myeloma allow Abnormal renal function allow due primary disease PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : See Disease Characteristics Creatinine clearance great 50 mL/min renal impairment Cardiovascular : No cardiac function would preclude study LVEF great 45 % Pulmonary : No pulmonary function would preclude study FVC great 60 % predict DLCO great 50 % predict Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No great 18 month prior alkylator exposure Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other See Disease Characteristics No 3 prior treatment regimen allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>